The review covers how GLP-1 drugs touch metabolic, inflammatory and nerve survival pathways tied to Parkinson's. Protective effects so far come from lab and animal models.
Recap by typeshit. Full story at News-Medical.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A plain-language look at the science behind Lilly's oral GLP-1 pill, aimed at people finding weight harder to manage in middle age.
Close to three in four patients had trouble taking their GLP-1 consistently, and researchers say cost may be pushing people to quit early.
Loading…